1. Home
  2. SCLX vs PBHC Comparison

SCLX vs PBHC Comparison

Compare SCLX & PBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • PBHC
  • Stock Information
  • Founded
  • SCLX 2011
  • PBHC 1859
  • Country
  • SCLX United States
  • PBHC United States
  • Employees
  • SCLX N/A
  • PBHC N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • PBHC Major Banks
  • Sector
  • SCLX Health Care
  • PBHC Finance
  • Exchange
  • SCLX Nasdaq
  • PBHC Nasdaq
  • Market Cap
  • SCLX 81.7M
  • PBHC 108.9M
  • IPO Year
  • SCLX N/A
  • PBHC N/A
  • Fundamental
  • Price
  • SCLX $0.42
  • PBHC $17.37
  • Analyst Decision
  • SCLX Strong Buy
  • PBHC
  • Analyst Count
  • SCLX 3
  • PBHC 0
  • Target Price
  • SCLX $11.33
  • PBHC N/A
  • AVG Volume (30 Days)
  • SCLX 184.3K
  • PBHC 4.4K
  • Earning Date
  • SCLX 01-07-2025
  • PBHC 01-30-2025
  • Dividend Yield
  • SCLX N/A
  • PBHC 2.30%
  • EPS Growth
  • SCLX N/A
  • PBHC N/A
  • EPS
  • SCLX N/A
  • PBHC 0.25
  • Revenue
  • SCLX $50,833,000.00
  • PBHC $35,494,000.00
  • Revenue This Year
  • SCLX $32.77
  • PBHC N/A
  • Revenue Next Year
  • SCLX $50.71
  • PBHC N/A
  • P/E Ratio
  • SCLX N/A
  • PBHC $69.39
  • Revenue Growth
  • SCLX 9.41
  • PBHC N/A
  • 52 Week Low
  • SCLX $0.40
  • PBHC $11.41
  • 52 Week High
  • SCLX $2.63
  • PBHC $19.86
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 29.75
  • PBHC 49.02
  • Support Level
  • SCLX $0.43
  • PBHC $16.81
  • Resistance Level
  • SCLX $0.51
  • PBHC $17.92
  • Average True Range (ATR)
  • SCLX 0.06
  • PBHC 0.44
  • MACD
  • SCLX -0.01
  • PBHC -0.02
  • Stochastic Oscillator
  • SCLX 7.30
  • PBHC 69.61

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About PBHC Pathfinder Bancorp Inc. (MD)

Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.

Share on Social Networks: